Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 14;10(7):e004831. doi: 10.1136/jitc-2022-004831

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Overall survival analysis in ICI-treated cases. (A) Kaplan-Meier curve analysis. Both irGS (left) and TMB high (right) correlated with better survival outcome. (B) Stratification analysis by pairwise irGS and TMB status. The TMB-low non-irGS group showed the worst survival outcome. (C) Stratification analysis by irGS, TMB, and cancer type. The TMB-low non-irGS groups showed unfavorable outcomes when analyzed per cancer type. The TMB-high non-irGS groups are not shown due to insufficient subgroup size. (D) Cox hazard regression model analysis. Both irGS and TMB status (binary or continuous) were shown to be independent favorable prognostic factors even after adjusting for cancer type. ICI, immune checkpoint inhibitor; irGS, immune-reactive genomic subtype; TMB, tumor mutational burden.